Document is current
Any future updates will be listed below
-
Authors
Demarinis, Giuseppe
Yeung, Ian https://orcid.org/0000-0001-6497-8866
Preston, Ella
Patel, Praveen J. https://orcid.org/0000-0001-8682-4067
Huemer, Josef https://orcid.org/0000-0001-5238-8295
Hamilton, Robin D. https://orcid.org/0000-0003-2861-8761
Nicholson, Luke
Tucker, William R.
Montesel, Andrea https://orcid.org/0000-0002-1910-9976
- License Information
-
More Information
Article History
Received: 27 October 2025
Revised: 13 February 2026
Accepted: 23 February 2026
First Online: 14 March 2026
Competing interests
: GD: travel support from Roche, IY: educational grants from Roche. PJP: Consulting for Roche, Novartis, Bayer and Boehringer Ingelheim; speaker fees from Bayer and Roche. RDH: honoraria, lecture fees, travel, and research grants from Roche. LN: speaker fees from Roche, Bayer, AbbVie, Heidelberg; advisory board Roche, Bayer, AbbVie, Boehringer Ingelheim; research grants from Optos Plc. AM educational grants, travel, and speaker fees from Roche, Bayer. JH: speaker fees, travel from Bayer and Roche, advisory board, Roche. EP, and WRT have no financial disclosures related to this manuscript.
